UNSPSC 51183609: Insulin detemir

This classification denotes a therapeutic insulin with the molecular formula C267H402N64O76S6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 4FT78T86XV, chemically known as insulin (ox), 8a-l-threonine-10a-l-isoleucine-30b-l-threonine- but more generally known as insulin, which bears US NIH Compound Identifier 16129672. European Medicines Agency schedules Insulin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02689MIG.

UNSPSC 51183609 Insulin detemir is a Commodity code covering the procurement of this long-acting basal insulin product by state and local government agencies, typically through cooperative purchasing vehicles that aggregate demand across multiple jurisdictions. State and local buyers source insulin detemir as part of broader pharmaceutical supply agreements that serve public health systems, Medicaid programs, correctional facilities, and other government-administered health services. The procurement pathway emphasizes bulk purchasing through established wholesaler networks to achieve price competitiveness and supply chain security, with vendors required to demonstrate compliance with cGMP, the Drug Supply Chain Security Act (DSCSA), and FDA requirements while maintaining contractual relationships with authorized pharmaceutical distributors.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued a Request for Proposal on January 20, 2026 to establish multiple contracts for generic multi-source pharmaceuticals and OTC products serving participating state and local facilities across Minnesota and Oregon, with proposals due March 26, 2026. MMCAP's solicitation (S1070000015802) requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with awarded contracts effective July 1, 2026 and a two-year initial term. Evaluation emphasizes price competitiveness (75 percent weighting), supported by compliance with administrative file format, EDI capability, pricing certification, and fixed-price submission requirements. Vendors must maintain comprehensive insurance including $5,000,000 commercial general liability per occurrence and demonstrate pricing flexibility through flat-price, net-price, or WAC-minus structures; performance penalties range from $200 to $1,500 per violation for late reporting or missed onboarding timelines.